Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it will provide several updates to stockholders in advance of the Company’s upcoming Annual Meeting of Stockholders scheduled for June 23, 2025. These updates will provide content regarding the Company’s innovative business model and strategic growth initiatives, which management believes position the Company strongly for future value realization. Ahead of the annual meeting, Tevogen intends to provide information on: Portfolio Assets: The Company will provide an update on its robust portfolio assets of Tevogen Bio Oncology, Tevogen Bio Specialty Care and Tevogen.AI, valued by investors well north of $10 billion in October 2024. This portfolio reflects the Company’s ability to potentially capitalize in a changing market and regulatory environment. Corporate Highlights: Tevogen will provide additional details on two strategic Company initiatives, Tevogen.AI and Tevogen Generics & Biosimilars. To support these initiatives, Tevogen is expanding its operational footprint with an upgraded headquarters. Financial Market Dynamics: Management continues to monitor the Company’s stock dynamics and recognizes the impact of a limited tradable float. Steadily growing institutional ownership of the Company’s stock, which management believes indicates strong investor confidence and long-term holding patterns, will also be highlighted. The Company remains deeply appreciative of the ongoing support from its investor community and will continue to provide clear and timely communication. Forward Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. ContactsTevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701Communications@Tevogen.com

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

FAQ

Why Bullish?

How important is it?

Why Short Term?

Related Companies

Related News